Lymphangioleiomyomatosis

European Journal of Internal Medicine

Volumn 20, Issue 1, 2009, Pages

  Fernández Fernández, Francisco José ^a   Buño Ramilo, Beatriz ^a   Sesma, Pascual ^b  

^a Universidad de La Coruña   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Doxycycline; Lymphangioleiomyomatosis; Matrix metalloproteinase

Indexed keywords

DOXYCYCLINE; ESTRADIOL; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ENZYME INACTIVATION; ENZYMURIA; HUMAN; LETTER; LUNG PARENCHYMA; LYMPHANGIOLEIOMYOMATOSIS; PATHOGENESIS; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME; UPREGULATION;

DOXYCYCLINE; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASES;

EID: 60349129271     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2008.07.020     Document Type: Letter

References (2)

1. Glassberg M.K., Elliot S.J., Fritz J., Catanuto P., Potier M., Donahue R., et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab 93 (2008) 1625-1633
2. Moses M.A., Harper J., and Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 354 (2006) 2621-2622